The landscape and therapeutic relevance of cancer-associated transcript fusions

K. Yoshihara, Q. Wang, W. Torres-Garcia, Siyuan Zheng, R. Vegesna, H. Kim, R. G.W. Verhaak

Research output: Contribution to journalArticle

172 Citations (Scopus)

Abstract

Transcript fusions as a result of chromosomal rearrangements have been a focus of attention in cancer as they provide attractive therapeutic targets. To identify novel fusion transcripts with the potential to be exploited therapeutically, we analyzed RNA sequencing, DNA copy number and gene mutation data from 4366 primary tumor samples. To avoid false positives, we implemented stringent quality criteria that included filtering of fusions detected in RNAseq data from 364 normal tissue samples. Our analysis identified 7887 high confidence fusion transcripts across 13 tumor types. Our fusion prediction was validated by evidence of a genomic rearrangement for 78 of 79 fusions in 48 glioma samples where whole-genome sequencing data were available. Cancers with higher levels of genomic instability showed a corresponding increase in fusion transcript frequency, whereas tumor samples harboring fusions contained statistically significantly fewer driver gene mutations, suggesting an important role for tumorigenesis. We identified at least one in-frame protein kinase fusion in 324 of 4366 samples (7.4%). Potentially druggable kinase fusions involving ALK, ROS, RET, NTRK and FGFR gene families were detected in bladder carcinoma (3.3%), glioblastoma (4.4%), head and neck cancer (1.0%), low-grade glioma (1.5%), lung adenocarcinoma (1.6%), lung squamous cell carcinoma (2.3%) and thyroid carcinoma (8.7%), suggesting a potential for application of kinase inhibitors across tumor types. In-frame fusion transcripts involving histone methyltransferase or histone demethylase genes were detected in 111 samples (2.5%) and may additionally be considered as therapeutic targets. In summary, we described the landscape of transcript fusions detected across a large number of tumor samples and revealed fusion events with clinical relevance that have not been previously recognized. Our results support the concept of basket clinical trials where patients are matched with experimental therapies based on their genomic profile rather than the tissue where the tumor originated.

Original languageEnglish (US)
Pages (from-to)4845-4854
Number of pages10
JournalOncogene
Volume34
Issue number37
DOIs
StatePublished - Sep 10 2015
Externally publishedYes

Fingerprint

Neoplasms
Therapeutics
Glioma
Phosphotransferases
Histone Demethylases
Genes
RNA Sequence Analysis
Mutation
Investigational Therapies
Gene Dosage
Genomic Instability
Glioblastoma
Head and Neck Neoplasms
Thyroid Neoplasms
Protein Kinases
Squamous Cell Carcinoma
Carcinogenesis
Urinary Bladder
Clinical Trials
Genome

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Yoshihara, K., Wang, Q., Torres-Garcia, W., Zheng, S., Vegesna, R., Kim, H., & Verhaak, R. G. W. (2015). The landscape and therapeutic relevance of cancer-associated transcript fusions. Oncogene, 34(37), 4845-4854. https://doi.org/10.1038/onc.2014.406

The landscape and therapeutic relevance of cancer-associated transcript fusions. / Yoshihara, K.; Wang, Q.; Torres-Garcia, W.; Zheng, Siyuan; Vegesna, R.; Kim, H.; Verhaak, R. G.W.

In: Oncogene, Vol. 34, No. 37, 10.09.2015, p. 4845-4854.

Research output: Contribution to journalArticle

Yoshihara, K, Wang, Q, Torres-Garcia, W, Zheng, S, Vegesna, R, Kim, H & Verhaak, RGW 2015, 'The landscape and therapeutic relevance of cancer-associated transcript fusions', Oncogene, vol. 34, no. 37, pp. 4845-4854. https://doi.org/10.1038/onc.2014.406
Yoshihara K, Wang Q, Torres-Garcia W, Zheng S, Vegesna R, Kim H et al. The landscape and therapeutic relevance of cancer-associated transcript fusions. Oncogene. 2015 Sep 10;34(37):4845-4854. https://doi.org/10.1038/onc.2014.406
Yoshihara, K. ; Wang, Q. ; Torres-Garcia, W. ; Zheng, Siyuan ; Vegesna, R. ; Kim, H. ; Verhaak, R. G.W. / The landscape and therapeutic relevance of cancer-associated transcript fusions. In: Oncogene. 2015 ; Vol. 34, No. 37. pp. 4845-4854.
@article{32b71a87775046558a695ddf17ddfe5a,
title = "The landscape and therapeutic relevance of cancer-associated transcript fusions",
abstract = "Transcript fusions as a result of chromosomal rearrangements have been a focus of attention in cancer as they provide attractive therapeutic targets. To identify novel fusion transcripts with the potential to be exploited therapeutically, we analyzed RNA sequencing, DNA copy number and gene mutation data from 4366 primary tumor samples. To avoid false positives, we implemented stringent quality criteria that included filtering of fusions detected in RNAseq data from 364 normal tissue samples. Our analysis identified 7887 high confidence fusion transcripts across 13 tumor types. Our fusion prediction was validated by evidence of a genomic rearrangement for 78 of 79 fusions in 48 glioma samples where whole-genome sequencing data were available. Cancers with higher levels of genomic instability showed a corresponding increase in fusion transcript frequency, whereas tumor samples harboring fusions contained statistically significantly fewer driver gene mutations, suggesting an important role for tumorigenesis. We identified at least one in-frame protein kinase fusion in 324 of 4366 samples (7.4{\%}). Potentially druggable kinase fusions involving ALK, ROS, RET, NTRK and FGFR gene families were detected in bladder carcinoma (3.3{\%}), glioblastoma (4.4{\%}), head and neck cancer (1.0{\%}), low-grade glioma (1.5{\%}), lung adenocarcinoma (1.6{\%}), lung squamous cell carcinoma (2.3{\%}) and thyroid carcinoma (8.7{\%}), suggesting a potential for application of kinase inhibitors across tumor types. In-frame fusion transcripts involving histone methyltransferase or histone demethylase genes were detected in 111 samples (2.5{\%}) and may additionally be considered as therapeutic targets. In summary, we described the landscape of transcript fusions detected across a large number of tumor samples and revealed fusion events with clinical relevance that have not been previously recognized. Our results support the concept of basket clinical trials where patients are matched with experimental therapies based on their genomic profile rather than the tissue where the tumor originated.",
author = "K. Yoshihara and Q. Wang and W. Torres-Garcia and Siyuan Zheng and R. Vegesna and H. Kim and Verhaak, {R. G.W.}",
year = "2015",
month = "9",
day = "10",
doi = "10.1038/onc.2014.406",
language = "English (US)",
volume = "34",
pages = "4845--4854",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "37",

}

TY - JOUR

T1 - The landscape and therapeutic relevance of cancer-associated transcript fusions

AU - Yoshihara, K.

AU - Wang, Q.

AU - Torres-Garcia, W.

AU - Zheng, Siyuan

AU - Vegesna, R.

AU - Kim, H.

AU - Verhaak, R. G.W.

PY - 2015/9/10

Y1 - 2015/9/10

N2 - Transcript fusions as a result of chromosomal rearrangements have been a focus of attention in cancer as they provide attractive therapeutic targets. To identify novel fusion transcripts with the potential to be exploited therapeutically, we analyzed RNA sequencing, DNA copy number and gene mutation data from 4366 primary tumor samples. To avoid false positives, we implemented stringent quality criteria that included filtering of fusions detected in RNAseq data from 364 normal tissue samples. Our analysis identified 7887 high confidence fusion transcripts across 13 tumor types. Our fusion prediction was validated by evidence of a genomic rearrangement for 78 of 79 fusions in 48 glioma samples where whole-genome sequencing data were available. Cancers with higher levels of genomic instability showed a corresponding increase in fusion transcript frequency, whereas tumor samples harboring fusions contained statistically significantly fewer driver gene mutations, suggesting an important role for tumorigenesis. We identified at least one in-frame protein kinase fusion in 324 of 4366 samples (7.4%). Potentially druggable kinase fusions involving ALK, ROS, RET, NTRK and FGFR gene families were detected in bladder carcinoma (3.3%), glioblastoma (4.4%), head and neck cancer (1.0%), low-grade glioma (1.5%), lung adenocarcinoma (1.6%), lung squamous cell carcinoma (2.3%) and thyroid carcinoma (8.7%), suggesting a potential for application of kinase inhibitors across tumor types. In-frame fusion transcripts involving histone methyltransferase or histone demethylase genes were detected in 111 samples (2.5%) and may additionally be considered as therapeutic targets. In summary, we described the landscape of transcript fusions detected across a large number of tumor samples and revealed fusion events with clinical relevance that have not been previously recognized. Our results support the concept of basket clinical trials where patients are matched with experimental therapies based on their genomic profile rather than the tissue where the tumor originated.

AB - Transcript fusions as a result of chromosomal rearrangements have been a focus of attention in cancer as they provide attractive therapeutic targets. To identify novel fusion transcripts with the potential to be exploited therapeutically, we analyzed RNA sequencing, DNA copy number and gene mutation data from 4366 primary tumor samples. To avoid false positives, we implemented stringent quality criteria that included filtering of fusions detected in RNAseq data from 364 normal tissue samples. Our analysis identified 7887 high confidence fusion transcripts across 13 tumor types. Our fusion prediction was validated by evidence of a genomic rearrangement for 78 of 79 fusions in 48 glioma samples where whole-genome sequencing data were available. Cancers with higher levels of genomic instability showed a corresponding increase in fusion transcript frequency, whereas tumor samples harboring fusions contained statistically significantly fewer driver gene mutations, suggesting an important role for tumorigenesis. We identified at least one in-frame protein kinase fusion in 324 of 4366 samples (7.4%). Potentially druggable kinase fusions involving ALK, ROS, RET, NTRK and FGFR gene families were detected in bladder carcinoma (3.3%), glioblastoma (4.4%), head and neck cancer (1.0%), low-grade glioma (1.5%), lung adenocarcinoma (1.6%), lung squamous cell carcinoma (2.3%) and thyroid carcinoma (8.7%), suggesting a potential for application of kinase inhibitors across tumor types. In-frame fusion transcripts involving histone methyltransferase or histone demethylase genes were detected in 111 samples (2.5%) and may additionally be considered as therapeutic targets. In summary, we described the landscape of transcript fusions detected across a large number of tumor samples and revealed fusion events with clinical relevance that have not been previously recognized. Our results support the concept of basket clinical trials where patients are matched with experimental therapies based on their genomic profile rather than the tissue where the tumor originated.

UR - http://www.scopus.com/inward/record.url?scp=84929852263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929852263&partnerID=8YFLogxK

U2 - 10.1038/onc.2014.406

DO - 10.1038/onc.2014.406

M3 - Article

C2 - 25500544

AN - SCOPUS:84929852263

VL - 34

SP - 4845

EP - 4854

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 37

ER -